SPATA5

Across TCGA pan-cancer cohorts, SPATA5 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SPATA5 data layer compared with 24 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SPATA5 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SPATA5 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where SPATA5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	III,IV	0.864	0.293	<.001	96	view →
LUAD	OS	Median	II,III,IV	0.454	0.805	.002	39	view →
PDAC	DFS	Median	All	0.565	0.332	.004	16	view →
HNSC	DFS	Median	IV	1.000	0.413	.033	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SPATA5–CCRCC (DFS)

Open the CCRCC breakdown →